A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-03-27

Study Completion Date

2027-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational study to collect data from Japanese babies with retinopathy of prematurity (ROP) who will be treated with Eylea. In observational studies, only observations are made without specified advice or interventions.

ROP is a condition that affects the eye and occurs only in babies who are born too early. Most cases of ROP are mild and get better without treatment, but more serious cases need to be treated in time. ROP happens when the blood vessels in the "retina" grow abnormally. The retina is the layer of tissue at the back of the eye that picks up light and sends messages to the brain. In babies with ROP, these abnormal blood vessels can leak. This causes damage to the retina and can sometimes move it out of place causing medical problems such as blindness.

Eylea is received as an injection into the eye. It works by blocking a certain protein (VEGF) that can cause blood vessels in the retina to grow abnormally. Eylea is already available in Japan and is approved for doctors to prescribe to babies with ROP.

The participants in this study are Japanese babies with ROP that their doctors decided to treat with Eylea before the start of this study. Babies with ROP that were already prescribed Eylea by their doctors may also be included.

The main purpose of this study is to collect more data on how safe the treatment with Eylea is in babies with ROP under a real-world setting. Another purpose of this study is to collect more data on how well Eylea works in these participants.

To see how safe Eylea is, the study doctors will collect all medical problems that the participants treated with Eylea have. These medical problems are called adverse events. Doctors keep track of all the adverse events that happen, even if they do not think that they might be related to the treatment.

To see how well Eylea works, the study doctors will check the number of participants:

* with no active ROP after starting treatment
* where ROP came back up to 6 months after start of treatment

In this study, the study doctor will:

* collect past data of the participants from medical records
* interview the participants
* collect treatment-related data during routine visits. The study duration is 6 months with 3 planned visits. One visit will be at start of treatment, one at one month and one at 6 months after start of treatment. All data required for this study will be collected during routine visits. Besides this data collection, no further tests or examinations are planned in this study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy

NCT04004208

Retinopathy of Prematurity (ROP)

COMPLETED PHASE3

Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome

NCT01578720

Choroidal Neovascularization Presumed Ocular Histoplasmosis

COMPLETED PHASE1

Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis

NCT03565887

Blepharoptosis

COMPLETED PHASE3

A Pharmacokinetics (PK) Study in Healthy Adults

NCT06911216

Blepharoptosis

COMPLETED EARLY_PHASE1

Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis

NCT01391273

Eyelash Hypotrichosis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retinopathy of Prematurity Newborns Infants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aflibercept treatment

The patients will be included in this study by investigators who are prescribing Aflibercept (AFL) routinely in their clinical practice. The enrollment of each patient in this study is able to accept at latest in 6 months from initiation of treatment.

Aflibercept (Eylea, BAY86-5321)

Intervention Type DRUG

Treatment with Intravitreal (IVT)-AFL must be made by the treating ophthalmologist

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aflibercept (Eylea, BAY86-5321)

Treatment with Intravitreal (IVT)-AFL must be made by the treating ophthalmologist

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of ROP requiring treatment
* Patients who have received IVT-AFL treatment according to Japanese approved labeling for AFL in ROP.
* ICF obtained from legal representative.

Exclusion Criteria

* Patients who have contradictions based on approved label
* Patients who have received IVT-AFL treatment before the treatment for the enrollment Patient.
* Diagnosis of other indication

Maximum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No